** daily **
** monthly **
Sept 5 (Reuters) - A federal court in Delaware on Tuesday invalidated patents held by Mallinckrodt Pharmaceuticals on its Inomax respiratory treatment system.
The ruling came in a lawsuit brought by Mallinckrodt against specialty chemical company Praxair Inc, which sought to market a generic version of Inomax. The judge found Praxair did not infringe Mallinckrodt's patents.
No comments:
Post a Comment